Abstract:Clinical Trials, Ahead of Print. The Patient-Centered Dosing Initiative, a patient-led effort advocating for a paradigm shift in determining cancer drug dosing strategies, pioneers a departure from traditional oncology drug dosing practices. Historically, oncology drug dosing relies on identifying the maximum tolerated dose through phase 1 dose escalation methodology, favoring higher dosing for greater efficacy, often leading to higher toxicity. However, this approach is not universally applicable, especially for newer treatments like targeted therapies and immunotherapies. Patient-Centered Dosing Initiative challenges this "more is better" ethos, particularly as metastatic breast cancer patients themselves, as they not only seek longevity but also a high quality of life since most metastatic breast cancer patients stay on treatment for the rest of their lives. Surveying 1221 metastatic breast cancer patients and 119 oncologists revealed an evident need for flexible dosing strategies, advocating personalized care discussions based on patient attributes. The survey results also demonstrated an openness toward flexible dosing and a willingness from both patients and clinicians to discuss dosing as part of their care. Patient-centered dosing emphasizes dialogue between clinicians and patients, delving into treatment efficacy-toxicity trade-offs. Similarly, clinical trial advocacy for multiple dosing regimens encourages adaptive strategies, moving away from strict adherence to maximum tolerated dose, supported by recent research in optimizing drug dosages. Recognizing the efficacy-effectiveness gap between clinical trials and real-world practice, Patient-Centered Dosing Initiative underscores the necessity for patient-centered dosing strategies. A focus on individual patient attributes aligns with initiatives like Project Optimus and Project Renewal, aiming to optimize drug dosages for improved treatment outcomes at both the pre- and post-approval phases. Patient-Centered Dosing Initiative's efforts extend to patient education, providing tools to initiate dosage-related conversations with physicians. In addition, it emphasizes physician-patient dialogues and post-marketing studies as essential in determining optimal dosing and refining drug regimens. A dose-finding paradigm prioritizing drug safety, tolerability, and efficacy benefits all stakeholders, reducing emergency care needs and missed treatments for patients, aligning with oncologists' and patients' shared goals. Importantly, it represents a win-win scenario across healthcare sectors. In summary, the Patient-Centered Dosing Initiative drives transformative changes in cancer drug dosing, emphasizing patient well-being and personalized care, aiming to enhance treatment outcomes and optimize oncology drug delivery.

Dose Optimization for Novel Oncology Agents: Design Options and Strategies

Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators

Dose Optimization of Targeted Therapies for Oncologic Indications

A Comparative Study of Adaptive Trial Designs for Dose Optimization.

Three steps towards dose optimization for oncology dose finding

Statistical and practical considerations in planning and conduct of dose-optimization trials

A Model‐Based Trial Design With a Randomization Scheme Considering Pharmacokinetics Exposure for Dose Optimization in Oncology

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

A seamless phase II/III design with dose optimization for oncology drug development

Dose optimization for cancer treatments with considerations for late-onset toxicities

Seamless Phase II/III Design: a Useful Strategy to Reduce the Sample Size for Dose Optimization

Optimizing dose-schedule regimens with bayesian adaptive designs: opportunities and challenges

A Bayesian Dynamic Model‐Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials

DROID: Dose-ranging Approach to Optimizing Dose in Oncology Drug Development

Oncology Combination Drug Development Strategies for Project Optimus

DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing—Challenging the "more is better" dogma

Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies

Adaptive Dose Modification for Phase I Clinical Trials